CTNM Stock Forecast: Contineum Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.68
−3.98% on the day

The 8 Wall Street analysts covering Contineum Therapeutics, Inc. hold a median 12-month price target of $22 — +153.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 32 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$340.8M
Ticker Nerd rank
32/ 100
Median analyst target
$22
Analysts covering
8
Revenue$0.0
Operating income−$17.4M
Net income−$15.2M
Free cash flow−$11.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.0%
1M
+2.6%
YTD
−24.1%
1Y
−29.0%
From 52W high
−50.6%
From 52W low
+22.6%
$7
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Contineum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
32/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
66
Quality
52
Momentum
51
Volatility
51
Value
47
Accruals
39
Issuance
25
Revisions
23

Growth (66): Sales and profits are climbing, and climbing faster than before.

Revisions (23): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CTNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26CTNMHigh $30Median $22Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
6
Buy
2
Hold
0
Sell
$14
Low
$22
Median
$30
High

The green dot is the last close — the median target sits +153.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
15 Oct 2026Jones TradingMaintainsBuy$24 → $30
14 Oct 2026BairdDowngradeNeutral$19 → $14
28 Sept 2026Morgan StanleyMaintainsEqual-Weight$18 → $17
15 Sept 2026BairdMaintainsOutperform$20 → $19
15 Sept 2026Jones TradingMaintainsBuy$26 → $24
31 July 2026RBC CapitalMaintainsOutperform$22 → $23
14 May 2026Morgan StanleyMaintainsEqual-Weight$14 → $16
6 Mar 2026BairdMaintainsOutperform—
8 Jan 2026Morgan StanleyDowngradeEqual-Weight—
24 Nov 2025BairdMaintainsOutperform—
21 Nov 2025RBC CapitalMaintainsOutperform—
25 Sept 2025Leerink PartnersInitiatesOutperform—
18 Aug 2025Morgan StanleyMaintainsOverweight—
19 May 2025Morgan StanleyMaintainsOverweight—
15 May 2025RBC CapitalReiteratesOutperform—
13 Mar 2025Jones TradingInitiatesBuy—
7 Mar 2025BairdMaintainsOutperform—
7 Mar 2025Morgan StanleyAssumesOverweight$25
9 Jan 2025RBC CapitalReiteratesOutperform—
7 Nov 2024RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTNM.

Market Radar

This page is one stock. Monday covers all of them.

CTNM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CTNM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Contineum Therapeutics, Inc. returned −29.0% against +6.9% for the S&P 500, dividends included.

CTNM vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26CTNMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CTNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.4×

Cheaper than 57% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−29.8%

Higher than 28% of US stocks

Return on assets
−20.2%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Contineum Therapeutics, Inc. has a market value of $340.8M and an enterprise value of $102.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$57.6M.

  • Diluted earnings per share, trailing twelve months: −$1.73.

  • Free cash flow in the twelve months to 30 June 2026: −$53.5M.

  • Shares outstanding: 37.6M.

  • Contineum Therapeutics, Inc. employs 51 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

CTNM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTNMContineum Therapeutics, Inc.$340.8M32
LYELLyell Immunopharma, Inc.$338.2M80
LRMRLarimar Therapeutics, Inc.$331.6M29
YDESYD Bio Ltd.$342.2M3
MPLTMapLight Therapeutics, Inc.$330.1M16
INOInovio Pharmaceuticals, Inc.$329.7M49
ALECAlector, Inc.$346.2M94

Take a look at CTNM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Contineum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CTNM

What is the CTNM stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Contineum Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $14 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTNM stock a buy right now?

Of the 8 analysts covering Contineum Therapeutics, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Contineum Therapeutics, Inc. 32 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTNM?

As at 21 Nov 2026, Contineum Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (66 of 100).

Will CTNM stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +153.5% from the last close, and Ticker Nerd's factor model ranks Contineum Therapeutics, Inc. 32 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTNM stock forecast for 2030?

No analyst covering Contineum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $30 over the next 12 months.

How has CTNM stock performed over the past year?

Contineum Therapeutics, Inc. returned -29.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Contineum Therapeutics, Inc. do?

Contineum Therapeutics Inc. Class A Common Stock represents ownership in Contineum Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for neuroscience, inflammation, and immunology indications. The company’s current pipeline is centered on internally developed drug candidates designed to address conditions with significant unmet medical need, including programs targeting pulmonary fibrosis, chronic pain, depression, and multiple sclerosis.

Company

About Contineum Therapeutics, Inc.

Contineum Therapeutics Inc. Class A Common Stock represents ownership in Contineum Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for neuroscience, inflammation, and immunology indications. The company’s current pipeline is centered on internally developed drug candidates designed to address conditions with significant unmet medical need, including programs targeting pulmonary fibrosis, chronic pain, depression, and multiple sclerosis. Contineum Therapeutics works at the intersection of drug discovery and clinical development, advancing therapies intended to modulate specific biological pathways relevant to these disease areas. Its business is concentrated on research, development, and advancement of candidate medicines rather than commercial product sales, making the stock closely tied to progress in its clinical and regulatory pipeline. Based in San Diego, California, Contineum Therapeutics plays a specialized role in the biotechnology market as a developer of novel therapies for complex inflammatory and neurological disorders.

CEO Mr. Carmine N. Stengone MBA, MS · 51 employees · United States · https://www.contineum-tx.com